Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress
Retrieved on:
Freitag, Juni 14, 2024
The study being presented evaluated the molecular basis of inhibition of the stem cell factor (SCF)/c-Kit signaling pathway via briquilimab and its functional impact on healthy human HSC survival, proliferation, and differentiation.
Key Points:
- The study being presented evaluated the molecular basis of inhibition of the stem cell factor (SCF)/c-Kit signaling pathway via briquilimab and its functional impact on healthy human HSC survival, proliferation, and differentiation.
- Results from the study demonstrate that blocking of SCF/c-Kit signaling by briquilimab does not cause apoptosis of HSCs, and that HSCs cultured in the presence of briquilimab differentiate directly into CD34- cells with higher c-Kit expression and without increased CD38 expression.
- “We are pleased to present preclinical data demonstrating the effect of c-Kit inhibition on the HSC compartment,” said Wendy Pang, M.D., Ph.D., Senior Vice President, Research and Translational Medicine of Jasper.
- “While blocking of SCF/c-Kit signaling by briquilimab does lead to mast cell apoptosis, it is important that it does not have a similar effect on healthy HSCs, and these data indicate that briquilimab instead skews them towards a distinct alternative HSC differentiation pathway.